5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.06▼ | 2.08▼ | 2.10▼ | 2.06▼ | 2.02▼ |
MA10 | 2.11▼ | 2.08▼ | 2.07▼ | 2.03▼ | 2.03▼ |
MA20 | 2.05▼ | 2.05▼ | 2.04▼ | 2.01▲ | 2.05▼ |
MA50 | 2.02▼ | 2.02▼ | 2.04▼ | 2.00▲ | 2.95▼ |
MA100 | 2.05▼ | 2.12▼ | 2.12▼ | 2.07▼ | 2.96▼ |
MA200 | 2.13▼ | 2.02▼ | 2.00▼ | 2.77▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.013▼ | -0.004▼ | 0.001▲ | 0.009▲ | 0.059▲ |
RSI | 37.224▼ | 40.558▼ | 40.773▼ | 49.588▼ | 43.253▼ |
STOCH | 35.710 | 63.598 | 72.348 | 34.475 | 42.282 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -67.742 | -62.000 |
CCI | -153.952▼ | -121.027▼ | -75.883 | -10.876 | 51.290 |
Friday, August 15, 2025 12:36 AM
Elutia Inc (ELUT) reports robust EluPro sales growth and strategic partnerships, but faces ongoing financial hurdles and legal challenges.
|
Thursday, August 14, 2025 06:03 PM
EluPro's sequential growth accelerated from 84% Q4-to-Q1 to 49% Q1-to-Q2, with hospital penetration rising from 125 to 161 active systems. BioEnvelope revenue increased from $3.1 million in Q1 to $3.5 ...
|
Thursday, August 14, 2025 01:05 PM
Strong Clinical Demand: EluPro customers are delivering meaningfully higher value than our legacy BioEnvelope platform, CanGaroo. In the second quarter, average sales per EluPro customer were 130% ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 2.00 | 2.10 | 1.9181 | 2.02 | 88,992 |
14/08/25 | 2.13 | 2.215 | 2.0801 | 2.15 | 54,526 |
13/08/25 | 1.97 | 2.30 | 1.97 | 2.16 | 24,536 |
12/08/25 | 1.96 | 2.04 | 1.95 | 1.99 | 11,046 |
11/08/25 | 2.015 | 2.0699 | 1.9601 | 1.97 | 7,475 |
08/08/25 | 1.96 | 2.01 | 1.96 | 2.01 | 4,240 |
07/08/25 | 1.97 | 2.01 | 1.96 | 1.98 | 7,003 |
06/08/25 | 1.98 | 2.03 | 1.9313 | 1.97 | 14,754 |
05/08/25 | 1.95 | 2.06 | 1.95 | 2.04 | 35,169 |
04/08/25 | 2.00 | 2.0772 | 1.98 | 1.99 | 9,783 |
|
|
||||
|
|
||||
|
|